FIELD: pharmaceutics; medicine.
SUBSTANCE: object 1 is a method for the treatment of Alzheimer’s disease, including administration to a subject who needs it of a combination of therapeutically effective amount of an antibody against Aβ protofibrils and therapeutically effective amount of N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazine-7a-yl)-4-fluorphenyl]-5-difluormethylpyrazine-2-carboxamide and/or its pharmaceutically acceptable salt. Object 2 is a combination for use in the treatment of Alzheimer’s disease, containing an antibody against Aβ protofibrils and N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazine-7a-yl)-4-fluorphenyl]-5-difluormethylpyrazine-2-carboxamide and/or its pharmaceutically acceptable salt.
EFFECT: reduction in a level of Aβ42 in the brain and increase in power of electroencephalograms in ranges α1 (11-13 Hz) and β1 (13-22 Hz) with administration of a combination.
7 cl, 2 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY | 2008 |
|
RU2523894C2 |
| HUMANIZED MONOCLONAL ANTIBODY AGAINST Aβ AND ITS USE | 2020 |
|
RU2783528C1 |
| TREATMENT OF MUSCULAR WEAKNESS WITH ALKALINE PHOSPHATASES | 2017 |
|
RU2754558C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND TREATMENT OF LYSOSOMAL ENZYME DEFICIENCY IN SUBJECT WITH TYPE II MUCOPOLYSACCHARIDOSIS | 2023 |
|
RU2814280C1 |
| DOSING STRATEGY REDUCING CYTOKINE RELEASE SYNDROME FOR CD3/C20 BISPECIFIC ANTIBODIES | 2019 |
|
RU2799529C2 |
| BISPECIFIC ANTIBODIES TO HUMAN BETA-AMYLOID / HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USING THEM | 2016 |
|
RU2730682C1 |
| FUSED MOLECULE CAPABLE OF INDUCING NON-INFLAMMATORY PHAGOCYTOSIS | 2022 |
|
RU2823919C1 |
| GENETIC STRUCTURE FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE | 2018 |
|
RU2757932C2 |
| TREATMENT OF DISEASES BY MEANS OF EXPRESSION OF ENZYME WITH DEOXYRIBONUCLEASE (DNase) ACTIVITY IN LIVER | 2019 |
|
RU2773691C2 |
| METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH ANTIBODIES WHICH BIND TO THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2013 |
|
RU2718751C2 |
